WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO),  announced that it has entered into an agreement with Terumo Corporation that Terumo will take over WuXi Biologics’ drug product (DP) plant in Leverkusen, Germany for EUR 150 million. The transaction is expected to be concluded in 2025, subject to the satisfaction of customary closing conditions.

Divesting the Leverkusen facility is a strategic step in aligning with the company’s long-term growth to enhance agility, scale diversified solutions for its global clients, and address emerging needs worldwide. This decision will allow WuXi Biologics to exclusively focus on building large-scale global DP manufacturing capacities in Singapore while optimizing returns on assets for future growth.

As a result, WuXi Biologics has completed the strategic review of all sites and will focus on building and developing its current sites.